Life Sciences Strategy and Growth
Centre for Science and Policy Annual Conference

Simon Greaves
Head of Corporate Affairs, Europe

29 June 2017



AstraZeneca: Global dimensions (full year 2016)



$23bn Total Revenue

$21.3bn Product Sales

$1.7bn Externalisation

$5.9bn invested in R&D with research across **5** countries

120 projects in clinical development and **12 NMEs** in late-stage development

11 NME approvals in 2016 – and 29 since 2014

59,700 employees

More than **600** collaborations and partnerships globally

Manufacturing in **18** countries

AstraZeneca UK footprint

£2.0b in associated UK R&D (2015)
£4.7b exports (2015)
6 800 direct employees, 35 000 supported indirectly
£500m ongoing investment in new Cambridge research centre and global HQ
£200m ongoing investment in manufacturing, packaging and infrastructure in Macclesfield
£75m investment in flu vaccine manufacturing in Speke
Over 200 academic partnerships and 140 clinical trials in 2014
Supporting 80 PhDs and 8 clinical lectureships in Cambridge

As at 31 December 2016

Three strategic R&D sites close to global bioscience clusters

Gaithersburg (US)

Cambridge (UK)

Gothenburg (Mölndal) (SE)



Cambridge: the heart of UK bioscience



AstraZeneca’s Cambridge Research Centre, May 2017

The Future Opportunity: UK life sciences as world beater, leading in discovery, development and use of medical technologies

Leveraging the NHS to grow the sector

Funding basic and applied research



Creating UK business and economic value



Harnessing new technologies